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Abstract
Background: In certain cases, anti-idiotypic antibodies that recognize an antigen-combining site
of an antibody can mimic the structure and/or function of certain nominal antigens. This feature
makes them particularly useful if conventional experimental approaches fail to fulfil expectations,
especially when the molecule of interest is infectious, toxic or difficult to isolate and purify. We
suggest the application of an anti-idiotype concept to the field of prion biology, with the aim of
evoking a humoral immune response against the pathological isoform of the prion protein (PrPSc).
Different ways to induce anti-idiotypic responses were studied in mice and chickens using various
forms of V5B2, a PrPSc-specific monoclonal antibody we have described previously.
Results: The preparation of anti-idiotypic monoclonal antibodies was achieved with well-defined
strategies of immunization, selection and subsequent characterization. Our results demonstrate
that it is possible to induce a strong anti-idiotypic immune response against the V5B2 monoclonal
antibody in both xenogeneic and syngeneic experimental systems. From the competition seen
between polyclonal and monoclonal anti-idiotypic antibodies and the original immunogen, the P1
peptide, and even more importantly, the ultimate target antigen, PrPSc, we conclude that selected
antibodies bind to the antigen-combining site of the V5B2 monoclonal antibody and might even
resemble the PrPSc-specific epitope. The involvement of both antigen-combining sites in the
interaction between V5B2 and the most promising monoclonal anti-idiotypic antibody was further
supported by molecular docking.
Conclusion: The results of the present study not only provide an example of the successful
production of Ab2 monoclonal antibodies based on a well planned strategy for selection, but should
also provide a new experimental approach that is applicable to the field of prion diseases.
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According to the Network Theory of Niels Jerne, the
immune system is a network of interacting idiotypes that
is involved in the regulation of immune responses [1].
Anti-idiotypic (Ab2) antibodies are a special set of anti-
bodies that can react with idiotopes, which represent
unique antigenic determinants on the surface of an anti-
body. Each antibody constitutes a small set of idiotopes
that form its own idiotype. Private idiotopes have been
shown to be associated with the complementarity-deter-
mining regions (CDRs), which, in addition to various
rearrangements of V-(D)-J gene segments, also reflect ran-
dom somatic mutations and/or N-region additions with a
low probability of repetition in another individual.
Unlike private idiotopes, recurrent idiotopes are encoded
by germline genes, which can generally tolerate some
somatic mutations without the loss of the original idi-
otope [2]. A single idiotope can stretch over a part of the
CDR and a part of the framework region, as well as over
both the light and heavy chain residues.
Ab2 antibodies can be classified into three distinct groups:
the Ab2α antibody group are conventional antibodies
that recognize idiotopes distinct from the antigen-com-
bining site on primary Ab1 antibodies; Ab2β antibodies
are internal image antibodies that recognize epitopes
within the antigen-combining site and that resemble the
nominal antigen (internal image); and Ab2γ antibodies
recognize epitopes within the antigen-combining site, but
do not resemble the nominal antigen [3].
The most intriguing group of Ab2 antibodies are those of
Ab2β, the internal image antibodies, which are directed
against the binding site of the eliciting antibodies and can,
in their paratope, structurally and/or functionally mimic
the original antigen, or more precisely, the epitope of the
original antigen [4-8]. This feature has led to the idea of
using internal image antibodies as surrogate antigens for
the development of active vaccines. Such an approach is
especially useful when the hypothetically protective anti-
gens are infectious, toxic or difficult to isolate and purify,
as is the case in prion disease vaccine development.
Prion diseases, which are also known as transmissible
spongiform encephalopathies (TSEs), are a group of
incurable, fatal neurodegenerative diseases that affect
humans and animals [9,10]. According to the widely
accepted "protein only" hypothesis proposed by Stanley
B. Prusiner, TSEs are caused by misfolding of the normal
cellular prion protein (PrPC) into the protease-resistant
isoform, PrPSc, which then accumulates in the central
nervous system [10,11]. Since the epidemic of bovine
spongiform encephalopathy (BSE) in the nineties and the
transmission of the disease to humans as variant Creut-
zfeldt-Jakob disease (vCJD) [12,13], significant scientific
resources have been devoted to improve our understand-
ing of prion biology. Interestingly, to date, it has not been
possible to detect a significant anti-PrPSc immune
response during the course of prion diseases [10,14,15].
Similar difficulties emerge with attempts to experimen-
tally evoke a protective anti-PrPSc immune response in
wild-type animals, when the recombinant prion protein
or peptides derived from the amino-acid structure of the
prion protein are used as antigens for immunization [16-
21]. Since the prion protein is a highly conserved ubiqui-
tous protein, it induces strong B-cell and T-cell immune
tolerance when introduced into an organism [20,22].
As an alternative to conventional active anti-prion vaccine
development, the Ab2 approach offers another way to
overcome the unresponsiveness of the immune system.
For the development of Ab2 antibodies that mimic the
PrPSc-specific epitope, a PrPSc-specific antibody is a pre-
requisite. In our previous studies, we described and char-
acterized V5B2, a PrPSc-specific monoclonal antibody,
and indicated its potential applicability for diagnostic
purposes [23,24]. Based on biophysical studies, it has
been proposed that V5B2 recognizes an epitope on PrPSc
that is similar or identical to the conformation of the P1
peptide in solution (predominantly a dimeric/oligomeric
form) and in fibril-like aggregates, both of which differ
from the conformation of the corresponding region in
PrPC [25].
According to the internal image phenomena, Ab2β anti-
bodies against the V5B2 paratope would carry the PrPSc-
specific epitope image in their antigen-combining site,
thereby providing an insight into its structure and maybe
even serving as a tool for idiotypic vaccine studies.
The aim of this study was thus to investigate the applica-
ble ways to induce an anti-idiotypic response to the PrPSc-
specific monoclonal antibody in xenogeneic and syn-
geneic experimental systems, and to define the prepara-
tion of Ab2 monoclonal antibodies with well-defined
strategies for immunization, selection and subsequent
characterization.
Results
To evoke an immune response against the idiotype of the
mouse V5B2 monoclonal antibody, two different models
of experimental immunization were set up: the xenoge-
neic and syngeneic experimental systems.
Anti-idiotypic response in chickens
In the xenogeneic experimental model, the chickens were
immunized with the mouse V5B2 monoclonal antibody.
The humoral immune response was monitored by detec-
tion of antigen specific IgY in the immune sera after the 3rd
immunization by ELISA (Fig. 1A). In particular, the OD405Page 2 of 14
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100-, 1,000- and 10,000-fold dilutions, respectively.
Hardly any signal could be detected at dilutions ≥
100,000-fold (OD405 0.15 ± 0.05). Since our specific inter-
est was restricted to Ab2 antibodies only, the competition
between chicken Ab2 antibodies and the original antigen,
the P1 peptide, for binding to the paratope of the V5B2
monoclonal antibody offered an insight into the Ab2
humoral response (Fig. 1B). The two chickens with sera
that exhibited the highest inhibition were further immu-
nized, although this time with the Fab fragment of V5B2,
to induce proliferation of Fab V5B2-specific B-cell clones
only. Unfortunately, none of the resulting hybridoma cell
clones maintained specific IgY production (data not
shown). To better characterize the potent polyclonal
immune response against the idiotype region, the Fab
V5B2 specific antibodies were purified from the chicken
blood sera. As shown in Fig 1C, the Ch5 immunoaffinity-
purified polyclonal Ab2 antibodies had an inhibitory
capacity of 100% when used at the concentration of only
2 μg/ml, whereas it declined to around 10% at the concen-
tration of 3.2 ng/ml.
Anti-idiotypic response in syngeneic mice
In the second experimental model, syngeneic BALB/c
mice were challenged with three different forms of the
same IgG1 molecule: the whole V5B2 monoclonal anti-
body, the Fab fragment of V5B2, and the Fab fragment of
V5B2 covalently coupled to the highly immunogenic car-
rier molecule KLH. Ten days after the 3rd immunization,
blood was taken from the tail vein and the sera were tested
for specific antibodies by indirect ELISA, and for Ab2 anti-
bodies by competitive ELISA, as shown in Fig 2. The mean
OD405 values at a 1:100 dilution were 1.11 ± 0.22, 1.40 ±
0.24 and 1.08 ± 0.3 for sera of mice immunized with
V5B2, Fab V5B2 and Fab V5B2-KLH, respectively. The
anti-V5B2 sera values declined faster with further dilu-
tions, as compared to the anti-Fab V5B2 and anti-Fab
The chicken immune response as monitored by detection of antigen-specific IgYFigure 1
The chicken immune response as monitored by detection of antigen-specific IgY. (A) ELISA: chicken sera were 
tested at 10-fold dilution steps starting from a 1:100 dilution. The serum before immunization was used as the negative control. 
Each line represents the mean absorbance of 5 individual chicken sera ± standard deviation. (B) Competition assay for polyclo-
nal chicken sera: for the competition assay, V5B2 was pre-incubated with the chicken sera that had been previously immunized 
with V5B2, and the subsequent binding ability of V5B2 to the P1 peptide was measured by ELISA. Each column represents the 
mean inhibition of V5B2 binding to the P1 peptide from the 4 individual chicken sera with the highest antibody titres ± standard 
deviation. (C) Competition assay for immunity purified chicken IgY (Ch5): each column represents the mean inhibition of V5B2 
binding to the P1 peptide of at least three experiments ± standard deviation.Page 3 of 14
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± 0.24 and 0.35 ± 0.17, respectively, at a dilution
1:10,000. In agreement with these data, the most potent
binding inhibition of V5B2 to the P1 peptide in ELISA was
seen with the anti-Fab V5B2 and anti-Fab V5B2-KLH sera.
More than 90% inhibition was reached with the anti-Fab
V5B2 and anti-Fab V5B2-KLH sera diluted to 1:1,000, and
more than 50% inhibition with these sera diluted
1:10,000 and 1:5,000, respectively. Since the highest
immune response against Fab V5B2 and the strongest
competition of Ab2 antibodies in immune sera were seen
in mice immunized with Fab V5B2, the two mice with the
highest anti-Fab V5B2 antibody titres were chosen and
sacrificed for the cell fusion. In addition, the mouse with
the highest anti-Fab V5B2 titre from the group of mice
immunized with Fab V5B2-KLH was also selected for the
cell fusion.
Ab2 monoclonal antibody selection
The selection of murine Ab2 monoclonal antibodies was
designed as a two-step process, including positive and
negative selection. In the positive selection step, only
hybridoma lines that reacted with Fab V5B2 in ELISA were
selected for further characterization, whereas in the fol-
lowing negative selection step, only cell lines that did not
bind to any of the negative selection proteins (the mono-
clonal antibodies and Fab fragments listed in Table 1)
were chosen. In particular, the first protein used for nega-
tive selection was the Fab fragment from the E12/2 anti-
recombinant bovine prion protein monoclonal antibody
[26], which has a different epitope specificity but is of the
same isotype as V5B2. This served to eliminate hypotheti-
cal isotype-specific antibodies that recognize the CH1
domain, the first constant domain, in addition to the var-
iable domain that was also present in the Fab fragment.
All of the further proteins used for negative selection were
Fab fragments of monoclonal antibodies directed against
the same P1 peptide as V5B2 [23]. These antibodies differ
from V5B2 either in terms of their prion protein isoform
specificities or other binding properties, as summarized in
Table 1.
The nucleotide and amino-acid sequences of the variable
domains of both the light and heavy chains of the anti-P1
antibodies were determined in our previous studies (man-
uscript in preparation). To compare not only their specif-
icity, but also their structural determinants, the amino-
acid identities and similarities between the variable
The mice immune responses elicited against different antigensFigure 2
The mice immune responses elicited against different antigens. (A) ELISA: immune sera were tested at 10-fold dilu-
tion steps starting from a 1:100 dilution. Pre-immune serum was used as the negative control. Each line represents the mean 
absorbance of 5 individual mice sera ± standard deviation. The antigens used for the immunizations are listed in the upper right 
corner. (B) Competition assay: V5B2 was pre-incubated with the serially diluted sera of mice immunized with different forms of 
V5B2 (listed in the upper right corner) and the V5B2 binding to the P1 peptide was measured by ELISA. Each column repre-
sents the mean absorbance of 4 individual mice sera with the highest antibody titres ± standard deviation.
Table 1: The monoclonal antibodies used in the negative selection process.
mAb Form of mAb Antigen used for mice immunization Isotype Specificity Reference
E12/2 Fab recBoPrP IgG1 PrPC, PrPSc, α1-helix [26]
C1/1 Fab P1 (HuPrP: 214–226) IgG1 PrPSc, PrPC [23]
K4H5 Fab P1 (HuPrP: 214–226) IgG1 PrPSc [23]
E9/5 IgG P1 (HuPrP: 214–226) IgG2a PrPSc [23]
recBoPrP, recombinant bovine prion protein; HuPrP, human prion proteinPage 4 of 14
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that were used for negative selection were examined.
According to the identity and similarity matrices, the clos-
est resemblance of VL and VH of V5B2 were seen with the
C1/1 and K4H5 monoclonal antibodies. In particular, the
VL of C1/1 was 85% identical and 91% similar to the VL of
V5B2 and the VH of K4H5 was 90% identical and 93%
similar to the VH of V5B2, with respect to the primary pro-
tein structures. The differences between these antibodies
were predominantly restricted to the CDR regions only, as
indicated by the frequencies of non-conserved substitu-
tions (NCS) and insertions and deletions (INDEL) inside
and outside these regions (Table 2). Still, all selected Ab2
antibodies exclusively recognize Fab V5B2 (Fig. 3A).
In all, 44 hybridoma cell lines that were obtained in four
cell fusions produced antibodies that reacted with Fab
V5B2, although only five hybridoma cell lines corre-
sponded to our strict selection criteria, all of which origi-
nated from mice immunized with the Fab fragment of
V5B2 (see next section and Fig. 3A). According to the
binding affinities and the capacity to inhibit the binding
of V5B2 to the P1 peptide in ELISA, the two most potent
Ab2 antibodies (5D12 and 4F8) are further described
here. These selected Ab2 monoclonal antibodies had high
affinities for Fab V5B2 in indirect ELISA. The Kaff deter-
mined were 8.04 ± 0.19 × 108 M-1 and 1.2 ± 0.02 × 109 M-
1 for 5D12 and 4F8, respectively.
Ab2 competition studies
Further characterization of the Ab2 monoclonal antibod-
ies in terms of competitive studies showed concentration-
dependent inhibition of V5B2 binding to the P1 peptide,
with over 55% and over 35% inhibition in the presence of
50 μg/ml 5D12 and 4F8, respectively. The isotype control
6C5 monoclonal antibody did not cause any significant
inhibition over a wide range of concentrations (Fig. 3B).
Since the P1 peptide is only a mimic of the PrPSc-specific
epitope on the PrPSc molecule, and since the final target is
the PrPSc molecule itself, we wanted to determine whether
Ab2 antibodies can inhibit the binding of V5B2 to PrPSc
directly in immunohistochemistry of brain slices of a
sCJD affected individual. Fig 4 shows the results of immu-
nohistochemical staining in the presence of different
competitor molecules through representative photomi-
crographs of labelled tissue sections (Fig. 4A) and in a
graphical form (Fig. 4B).
Preincubation of V5B2 with its original antigen, the P1
peptide (at 10 μg/ml), resulted in a 92% reduction in the
signal relative to the positive control (p < 0.004), while
the scrambled P1 peptide (Pscr) at the same concentration
(10 μg/ml) caused a statistically non-significant decrease
in comparison to the positive control. Preincubating
V5B2 with the 5D12 and 4F8 Ab2 monoclonal antibodies
at 100 μg/ml resulted in a 90% and 50% drop in the sig-
nal, respectively. Both of these effects were statistically sig-
nificant (p < 0.004). A 50 μg/ml concentration of 5D12
still caused a significant, 52% drop in signal, whereas fur-
ther dilution of 5D12 to 10 μg/ml had a lesser effect,
reducing the signal by 39%, which did not reach statistical
significance. The isotype negative control antibody at 100
μg/ml again produced a statistically non-significant effect
compared to the positive control. All three concentrations
of the purified Ch5 chicken polyclonal Ab (10, 1 and 0.1
μg/ml) caused large and highly significant (p < 0.004) sig-
nal decreases, of 88%, 84% and 81%, relative to the posi-
tive control.
Ab2 monoclonal antibody selection and the binding competition in ELISAFigure 3
Ab2 monoclonal antibody selection and the binding competition in ELISA. (A) Positive and negative selection steps. 
Each column represents the immunoreactivity of individual Ab2 antibodies to the coated positive/negative selection antigens in 
the selection process. Each Ab2 antibody was used at 1 μg/ml. (B) Ab2 monoclonal antibody competition between the Ab2 
antibody and the P1 peptide for the binding to V5B2. Each column represents the mean inhibition of at least three experiments 
± standard deviation.Page 5 of 14
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molecular docking
The nucleotide and amino-acid sequences of VH and VL
were determined [EMBL:AM850706, EMBL:AM850707
and EMBL:FM180446, EMBL:FM180447 for VH and VL of
5D12 and 4F8, respectively]. According to the results of
the competitive studies, 5D12 was chosen as the most
promising monoclonal Ab2 and its interaction with V5B2
was further characterized with molecular docking.
The Patchdock algorithm generated 3845 matches
between the 5D12 and V5B2 models based on their sur-
face complementarity. The 100 best solutions were further
refined and scored using the Firedock algorithm. In the
solution that shows the best surface complementarity, the
molecular interface between 5D12 and V5B2 was formed
by the CDR regions of both models (Fig. 5A). At the same
time, this orientation had the 3rd lowest global energy of
all the matches scored using Firedock. The two solutions
with the lower global energy only ranked 37th and 34th
with respect to the complementarity and both proposed
binding to the C-terminal face of the V5B2 model. As this
surface is an artifact of the model, which contains only
variable regions of both chains, and is not exposed in the
entire mAb or Fab fragment, these two solutions were dis-
carded as irrelevant.
The amino-acid residues that form the 5D12-V5B2 con-
tact interface were identified as the ones, in which any
atom of the residue is separated from any binding partner
atom by a distance ≤ 4 Å. For both binding partners the
majority of the contact residues were found to be located
in the CDR loops: 19/20 and 18/20 contact residues in the
case of 5D12 and of V5B2, respectively (Figs. 5C and 5D).
With the exception of CDR-L2, all CDR loops from 5D12
contributed to the 5D12-V5B2 binding surface.
The comparison of the P1 peptide sequence (CITQY-
ERESQAYY) and the 5D12 interacting surface residues
revealed several similarities. The centre of the 5D12 inter-
face is composed of aromatic residues, especially Tyr,
which correspond to the C-terminal Tyr-Try motif of the
P1 peptide. In addition the polar Ser and Thr residues,
separated from the Tyr patch by an Asn residue resemble
the Ser-Gln motif in the P1 peptide sequence (Fig. 5B).
Discussion
Over the past decade, the anti-idiotypic vaccine approach
has been successfully used for various aspects of vaccinol-
ogy, such as autoimmune diseases, enteric intoxification,
rejection of allografts, allergic diseases, foetal immunity
regulation, and in particular, tumour immunotherapy
[27]. This is the method of choice when the surrogate pro-
tective antigens are carbohydrate moieties or glycopro-
teins, when protective antigens are difficult to isolate and
purify, when synthetic peptides cannot form the tertiary
structure present in protective antigens, and when infec-
tious agents with unpredictable effects are used [28-31].
Some of the properties listed also hold true for the patho-
logical form of the prion protein. Induction of protective
anti-prion immune response in wild type animals is
extremely difficult, because of the host tolerance to
endogenous PrPC (for review see [21]). To date, no
entirely successful attempt of active immunization in the
field of TSE has been published, although some hypothet-
ically protective target sites on the prion protein have been
proposed [18,19]. However, to our knowledge, no
method has been widely accepted. Anti-idiotypic vaccines
would therefore represent a novel approach for prion dis-
ease prevention and treatment.
Results of passive vaccination and cell-culture studies
indicate that only monoclonal antibodies that bind to the
membrane PrPC are efficient in blocking prion propaga-
tion and pathogenesis [32-35]; at the same time, it has
been shown that monoclonal antibodies that recognized
both PrPC and PrPSc, blocked PrPSc accumulation in vitro
even more efficiently than monoclonal antibodies specific
for PrPC only [36]. However, the cross-linking of PrPC in
vivo caused extensive neuronal damage [37] and in our
Table 2: Comparison of V5B2 and the antibodies used for the negative selection.
V5B2 VH V5B2 VL
Frequency of NCS and INDEL Frequency of NCS and INDEL
identity similarity inside CDR outside CDR identity similarity inside CDR outside CDR
K4H5 VH 0.902 0.927 0.16 0.01 K4H5 VL 0.534 0.698 0.61 0.09
C1/1 VH 0.685 0.774 0.28 0.06 C1/1 VL 0.847 0.910 0.16 0.01
E9/5 VH 0.457 0.630 0.31 0.09 E9/5 VL 0.590 0.718 0.28 0.10
NCS, non-conserved substitutions; INDEL, insertions and deletions;
Amino-acid identities and similarities between the variable regions of the heavy and light chains of the V5B2 monoclonal antibody, in comparison to 
the variable regions of the heavy and light chains of the other monoclonal antibodies used for negative selection. The amino-acid identities and 
similarities were calculated using the BLOSUM62 matrix.Page 6 of 14
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opinion this finding needs to be noted when potent PrPC-
specific antibodies are to be induced or introduced for
treatment or prophylaxis purposes. Therefore an approach
to exclusively target PrPSc would avoid all of the problems
regarding the binding of antibodies to PrPC and the result-
ant cessation of normal PrPC function.
To directly target the pathological isoform in the develop-
ment of an anti-idiotypic vaccine, a PrPSc-specific anti-
body is a prerequisite. However, only a few PrPSc-specific
antibodies have been reported [23,24,38-40], and due to
their individual characteristics, not all of them are suitable
for this purpose.
Competitive immunohistochemical studiesFigur  4
Competitive immunohistochemical studies. (A) Representative photomicrographs of immunohistochemically stained 
sCJD cerebellar cortex sections in the absence and presence of different competitor molecules. The brown precipitate in the 
Purkinje cells layer and internal granular cell layer indicates specific prion immunoreactivity to a variable degree in all of the 
images except the negative control. Only photomicrographs of sections stained with the use of following concentrations of 
competitor molecules are shown: 100 μg/ml for isotype control, 5D12 and 4F8, and 10 μg/ml for Ch5, P1 and Pscr. (B) Bar 
chart showing the effects of different competitor molecules at varying concentrations on the mean immunohistochemical signal 
intensity, expressed as percentages of the uncompeted V5B2-HRP immunoreactive signal intensity (positive control). Asterisks 
indicate statistically significant (p < 0.004) reductions in the mean signals. Competitor molecule concentrations are given in μg/
ml in brackets.(page number not for citation purposes)
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described by our group is a potent PrPSc-specific antibody
that reacts with the native PrPSc deposits in immunohisto-
chemistry [24]. This thus represents an appropriate candi-
date to preserve the information of the native PrPSc-
specific epitope in its antibody-combining site. In the
present study, the main ways of producing Ab2 antibodies
against the PrPSc-specific antibody have been studied in
two experimental models: in xenogeneic and syngeneic
systems.
Mammalian proteins are highly immunogenic in chick-
ens. As expected for xenogeneic immunization, the anti-
body titre in the antiserum was high. Although the
immune response was expected against the whole immu-
noglobulin molecule, anti-idiotypic response was surpris-
ingly potent, with the ability to totally block the binding
of V5B2 to the P1 peptide or PrPSc. However, despite
promising results after testing the immune sera and affin-
ity purified Ab2 IgY antibodies, we were not able to isolate
stable chicken hybridoma cell lines that retained the anti-
body production. The main reason appears to be that to
date chicken hybridoma technology has been poorly stud-
ied in comparison to mouse hybridoma technology; the
system therefore still needs to be optimized for use as a
routine experimental procedure.
In our syngeneic studies, the antigen (Ab1 V5B2) was
actually a self-protein, produced in a BALB/c mouse and
injected into an inbred BALB/c mouse with virtually the
same genetic background, and therefore self-tolerance to
the whole constant part of the immunoglobulin was
expected. Groups of BALB/c mice were immunized with 3
different forms of the same antigen. Whole IgG V5B2 was
the original and the least chemically treated molecule
used for immunization. It is a relatively large molecule,
predominantly composed of the self constant region, with
only a minor part being immunogenic in a syngeneic
experimental system. Although the immune tolerance to
the whole constant part of the immunoglobulin molecule
was expected, we also wanted to assess whether the use of
the smaller fragment Fab V5B2, lacking the constant Fc-
region, potentiates the immune response to idiotopes. In
addition to the whole V5B2 and Fab V5B2, the Fab V5B2,
covalently coupled to the highly immunogenic carrier
molecule KLH, was used for immunization, to maximize
the specific helper T-cell response and to potentiate the
immune response against idiotopes on V5B2. Neverthe-
less, a prominent immune response was achieved with all
three antigens. Surprisingly, even though the immune
response against the whole IgG V5B2 was relatively
strong, the antisera capacity to inhibit the V5B2 binding
to the P1 peptide was much lower in comparison to the
inhibitory capacity of the antisera obtained by immuniza-
tion with the smaller fragment, Fab V5B2. Because of the
higher molecular weight of the whole IgG V5B2 in com-
parison to the Fab V5B2, less idiotopes of V5B2 are
present per μg of antigen injected in case of the whole IgG.
This could contribute to the lower immune response and
lower inhibitory capacity of the obtained sera. It is also
possible that the immune response was directed predom-
inantly against the glycan moieties of the constant region
in case of the whole IgG, as the glycosylation profile of
monoclonal antibodies is affected by the cell culture con-
ditions and can differ from the normal antibody glyco-
sylation observed in vivo [41]. Based on the observed
inhibitory capacity, only the mice immunized with Fab
V5B2 and Fab V5B2-KLH were sacrificed for the cell
fusion. The resulting hybridoma cell lines produced pre-
dominantly IgG Ab2 antibodies, in contrast to other Ab2
antibody studies, where the antibodies were mainly of the
IgM class [4,5,42,43]. The obtained Ab2 antibodies
bound Fab V5B2 with a high affinity, characteristic of
affinity-matured IgGs.
The proposed model of the 5D12-V5B2 complex obtained with m lecular d ckingFigure 5
The proposed model of the 5D12-V5B2 complex 
obtained with molecular docking. (A) A ribbon diagram 
of the 5D12 and V5B2 variable regions illustrating the orien-
tation of both binding partners with the CDR regions located 
at the molecular interface. (B) The amino-acid residues form-
ing the putative 5D12 paratope. The residues from the VL 
and VH CDR regions are shown in yellow and orange, respec-
tively. The only contact residue that lies outside of the CDR 
regions is coloured in green. (C) A semi-transparent depici-
tion of the 5D12-V5B2 contact surface. The CDR loops from 
VL 5D12, VH 5D12, VL V5B2 and VH V5B2 are shown in yel-
low, orange, cyan and blue, respectively. Stick representation 
is used for all contact residues and wire representation of 
the backbone atoms is used for the remaining CDR residues. 
The contact residues that are not part of the CDR loops are 
coloured in green. The same representation, rotated for 
180° around the vertical axis, is show in (D).Page 8 of 14
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antibodies that recognize private idiotopes. Therefore, the
selection process included Fab fragments of monoclonal
antibodies with the same specificities for the peptide anti-
gen, but with different specificities for the prion protein
isoforms. Indeed, the majority of the antibodies used in
the negative selection process (Table 1) were directed
against the P1 peptide derived from the C-terminal
amino-acid sequence of the human prion protein, which
can adopt different conformations in solution, and there-
fore, which can elicit antibodies of different specificities
when injected into wild-type mice [23]. The comparison
of the variable region amino-acid sequences of both the
light and heavy chains, between antibodies that had been
used in the negative selection process and our antigen, Fab
V5B2, revealed considerable analogy. The VH and VL
amino-acid sequences of these antibodies differ only
slightly, and most importantly, the differences between
these antibodies are predominantly restricted to the CDR
regions (Table 2). Nevertheless, all of the Ab2 mono-
clonal antibodies selected still distinguished between the
Fab fragments of these antibodies, which indicated a very
precise selectivity of our Ab2 monoclonal antibodies for
private idiotopes, most probably restricted to the CDR
regions of V5B2. Subsequent in silico structural modelling
of the 5D12-V5B2 complex also revealed the close interac-
tion of both CDR regions (Fig. 5).
Based on the selection process described and the affinities
of the Ab2 antibodies for Fab V5B2 as well as their inhibi-
tion potential, two Ab2 monoclonal antibodies, 5D12
and 4F8, were selected for further characterization. Since
no functional test is available to determine the presence of
Ab2 antibodies that bind to the antigen-combining site of
a PrPSc-specific antibody, at first an ELISA-based inhibi-
tion assay was designed to characterize the Ab2 antibody
response. Ab2 antibodies in chicken and mouse polyclo-
nal immune sera and Ab2 murine monoclonal antibodies
(Figs. 1B, 1C, 2B and 3B) substantially inhibited the bind-
ing of Ab1 to the P1 peptide in a dose-dependent manner.
This indicated that in agreement with idiotypic network
theory, immunization with Fab V5B2 induced Ab2 anti-
bodies, which bear the functional epitope for Ab1 that
competes with the original antigen, the P1 peptide, and in
turn have to be similar to the P1 peptide structure. The
reasons for the stronger inhibition of the polyclonal
immune sera in comparison to monoclonal antibodies
can be accounted for by the higher antibody concentra-
tion, a wider variety of Ab2 antibody specificities, and
consequently also a wider variety of target epitopes
present in polyclonal preparations.
In addition to the ELISA-based inhibition assay, the com-
petitive immunohistochemistry assay was set up to show
that Ab2 antibodies inhibit not only binding of V5B2 to
the P1 peptide but also to the original target molecule,
PrPSc. Indeed, we observed 90% and 50% inhibition of
binding of V5B2 to PrPSc using high concentrations of
5D12 and 4F8, respectively, whereas the isotype control
did not show any significant inhibition at the same con-
centrations. The inhibition of binding was concentration
dependent, which indicates the specificity of the effects
seen. Furthermore we saw 88% inhibition with the use of
much lower concentrations of polyclonal Ch5 as compet-
itor, again probably due to a wider variety of Ab2 anti-
body specificities with synergistic effects, present in the
polyclonal preparation. The results of the competitive
immunohistochemical studies, together with the results
of the competitive ELISA, strongly indicate that the
selected Ab2 antibodies bind into the V5B2 binding site,
thereby hindering the binding of V5B2 to the P1 peptide,
and most importantly to the original target, the PrPSc mol-
ecule. In addition, the structural model of the 5D12-V5B2
complex, obtained by molecular docking, also strongly
supports the close interaction of both antibody-combin-
ing regions, since the majority of the interacting residues
are located in the CDR regions (Figs. 5C, 5D).
Based on previous studies, Ab2 antibodies can resemble
the amino-acid sequences of nominal antigens in their
variable regions, especially when the nominal antigen is a
peptide [44-46]. The P1 peptide motif could be preserved
in a single CDR sequence or in a conformational stretch
across different CDR loops of a single chain, as well as
across different loops of both the heavy and light chains.
The latter, i.e. the involvement of different CDR loops of
both chains, is also evident from the proposed model of
the 5D12-V5B2 complex. The comparison of the 5D12
binding interface to the P1 peptide reveals structural sim-
ilarities to its C-terminal. This is especially important in
the light of our recent unpublished data, which indicate
that the C-terminal residues are crucial for the V5B2 bind-
ing to the P1 peptide. It is therefore possible that the 5D12
binding surface mimics the crucial part of the P1 peptide
and the epitope, unique to the PrPSc molecule. Neverthe-
less, the computer modelling data must be interpreted
cautiously; still, the obtained docking model is in agree-
ment with the observed experimental data. The proposed
model also achieved an outstanding ranking score using
both the surface complementarity and the global energy
criteria.
Conclusion
With all of the data collected, we have shown that it is pos-
sible to induce a strong Ab2 antibody immune response
against a PrPSc-specific monoclonal antibody in both the
xenogeneic and the syngeneic experimental systems.
Among the three different antigens tested, the Fab frag-
ment was the most successful form for the immunization
of mice. In addition, we have demonstrated that it is pos-
sible to select Ab2 monoclonal antibodies specific for pri-
vate idiotopes using a two-step selection process. In ourPage 9 of 14
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nantly differ in CDR regions only, enabled the critical
selection step in the negative selection process. Ab2β, the
internal image antibodies, are directed against the binding
site of the eliciting antibody and are structural and/or
functional mimics of the original antigen. According to
the convincing results of the competition studies and the
computer modelling data, 5D12 is a highly plausible can-
didate for being an internal image antibody, mimicking
the PrPSc-specific epitope. The results of the present study
not only provide an example of the successful production
of Ab2 monoclonal antibodies based on a well planned
strategy for selection, but should also provide a new




Chickens from a divergently selected line (D+) for high
body weight [47] were bred and maintained in the
Department of Animal Science at the Biotechnical Faculty,
University of Ljubljana. BALB/c mice were bred and main-
tained in the Animal Facility at the Blood Transfusion
Centre of Slovenia. Both groups of animals were handled
in accordance with the FELASA recommendations and
guidelines.
Cell lines
V5B2 (Ab1), a B-cell hybridoma cell line of BALB/c origin,
was generated against the 13-residue synthetic P1 peptide
(CITQYERESQAYY), which was derived from the C-termi-
nal α-helix of the human prion protein (amino acids
214–226), coupled to keyhole limpet hemocyanin (KLH)
[24]. The NS1 murine myeloma cell line, the V5B2 hybri-
doma cell line and all murine hybridoma cell lines pre-
pared in this study were maintained in Dulbecco's
modified Eagle's medium (DMEM; ICN Biomedical) sup-
plemented with 13% bovine serum (HyClone), 2 mM L-
glutamine (Sigma), 130 μg/μl streptomycin (Sigma) and
100 U/ml penicillin (Sigma) (subsequently referred to as
DMEM+). The MuH1chicken myeloma cells and clones
obtained by fusion of chicken cells were cultured in
Iscove's Modified Dulbecco's medium (Sigma) with addi-
tion of foetal bovine serum (HyClone) and gentamycin
(Sigma) at final concentrations of 10% and 0.1%, respec-
tively.
Antigens
We prepared three different antigens for the immuniza-
tion: the whole V5B2 antibody, the Fab fragment of the
V5B2 antibody, and the Fab fragment of the V5B2 anti-
body coupled to KLH. All supernatants from murine
hybridoma cells were purified by gravity-flow affinity
chromatography on Protein G Sepharose (Amersham)
using 0.1 M glycine, pH 2.7, for elution. The Fab frag-
ments were produced by cleaving with immobilized
papain (Pierce) and purification on Protein A Sepharose
CL-4B (Pharmacia Biotech). The identity and purity of the
Fab fractions were determined by indirect ELISA and
Western blotting. The Fab fragments of V5B2 were cou-
pled to KLH via 4-maleimidobutyric acid N-hydroxysuc-
cinimide ester (GMBS, Sigma), according to the procedure
described by Yoshitake et al. [48].
Chicken immunization and fusion protocol
Five chickens were immunized intramusculary every 3
weeks with the whole V5B2 monoclonal antibody as anti-
gen. In each immunization, 400 μg of antigen was applied
into three places in the breast muscle, in a total volume of
1 ml. For the first immunization, the antigen was mixed
with Complete Freund's Adjuvant (1:1 v/v; Sigma), for the
second immunization, with Incomplete Freund's Adju-
vant (Sigma), and for all of the subsequent immuniza-
tions, with physiological saline. After the 4th
immunization, the titres of anti-V5B2 antibodies were
estimated by ELISA and the two chickens with the highest
antibody titres were selected. They received two more
boosters of the Fab fragment of V5B2. Three days after the
last immunization booster, these chickens were sacrificed,
and their blood was collected for the preparation of the
polyclonal anti-serum and their spleens were removed for
monoclonal antibody production.
The chicken hybridoma cells were produced as described
previously [49,50]. Briefly, spleen cells from the immu-
nized chickens were fused with the MuH1 chicken mye-
loma cell line in a ratio of 1:3 using 50% polyethylene
glycol. Hybridoma cells were selected while maintaining
the cells in medium containing HAT (hypoxanthine, ami-
nopterin, thymidine; Sigma) or HT (hypoxanthine, thy-
midine; Sigma), at a final concentration of 1%, and
ouabain (Sigma), at a final concentration of 20 μM.
Chicken polyclonal antibody affinity purification
Fab V5B2 was covalently immobilized to agarose beads
(Pierce) according to the manufacturer protocol. Blood
serum from the chicken with the most potent immune
response, collected after immunization, was applied to
the column with the immobilized Fab V5B2. After exten-
sive washing the bound fraction was eluted using 0.1 M
glycine, pH 2.7.
Mouse immunization and fusion protocol
Female BALB/c mice (6–8 weeks old) were immunized
with three different antigens: the whole V5B2 antibody,
the Fab fragment of the V5B2 antibody, and the Fab frag-
ment of the V5B2 antibody coupled to KLH. Each mouse
was immunized subcutaneously with 0.1 mg antigen in
Complete Freund's Adjuvant on day 0, and then intraperi-
toneally with 0.1 mg antigen in Incomplete Freund'sPage 10 of 14
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bled from the tail vein and the immune sera were col-
lected. A final booster of 50 μg antigen in physiological
saline was administered intravenously on day 57,
although only into the mice with the highest antibody
titres, which were the ones selected as spleen-cell donors
for the cell fusion. The mice were sacrificed on day 61, and
their spleens were removed. Splenocytes were isolated and
fused with mouse NS1 myeloma cells with 50% polyeth-
ylene glycol for 3 min, according to standard procedures.
Hybridoma cells were selected by maintaining the cells for
two weeks in HAT DMEM+ and another week in HT
DMEM+ selection medium (DMEM+ supplemented with
HAT or HT, respectively). The presence of specific anti-
bodies was determined in supernatants after 10 to 14 days
by indirect ELISA. Selected hybridomas were cultured
until stable cell lines were established, and then sub-
cloned by limiting dilution, and frozen in liquid nitrogen.
Murine anti-idiotypic monoclonal antibody selection
Microtitre ELISA plates (Nunc) were coated with 50 μl Fab
fragment at 1 μg/ml in 50 mM carbonate/bicarbonate
buffer, pH 9.6, and incubated overnight at 4°C. The next
day, the plates were washed three times with washing
buffer (sodium phosphate buffer, containing 150 mM
NaCl, 0.05% Tween 20, pH 7.2–7.4) and blocked for 30
min at 37°C with blocking buffer (1% BSA in washing
buffer). The plates were washed again and then incubated
with the following primary antibodies: polyclonal
immune sera, cell culture supernatant, or purified mono-
clonal antibodies, all diluted in blocking buffer, for 1.5 h
at 37°C. After washing, the plates were incubated with a
secondary goat anti-mouse IgG (γ-chain specific) conju-
gated to horseradish peroxidase (HRP, Sigma), diluted
1:3,000 in blocking buffer, and incubated again for 1.5 h
at 37°C. After incubation with the 2,2'-azino-bis(3-ethyl-
benzothiazoline-6-sulfonic acid) (ABTS, Sigma) substrate
in citrate-phosphate buffer, pH 4.5, for 20 min at 37°C,
the reaction was measured spectrophotometrically at 405
nm with a microtitre plate reader.
The 5D12 and 4F8 clones were chosen for further experi-
ments, as they consistently produced the highest titre anti-
bodies, as determined by indirect ELISA. The 6C5 murine
IgG1 monoclonal antibody, specific for antigen B of the
human polysaccharide blood group system AB0, served as
an isotype negative control monoclonal antibody
throughout the study.
Determination of affinity constants
The affinity constants (Kaff) of the Ab2 monoclonal anti-
bodies were determined in a non-competitive immu-
noassay [51]. Briefly, an ELISA plate (Nunc) was coated
overnight with Fab V5B2 at three different concentrations:
5 μg/ml, 2.5 μg/ml and 1.25 μg/ml. The Ab2 monoclonal
antibodies were applied at three-fold serial dilutions, with
concentrations ranging from 9 μg/ml down to 12 ng/ml.
The incubations with the secondary antibody and the
ABTS substrate were performed as described above.
Competitive ELISA
Chicken immune sera
For the competition studies, ELISA plates (Nunc) were
coated with 0.5 μg/ml P1 peptide (JPT) overnight. The
next morning, the plates were washed and blocked as
described above. Then 1 μg/ml V5B2 was separately
mixed with different dilutions of chicken immune sera
and incubated for 1 h at 37°C prior to application to the
blocked ELISA plate, with a further incubation for 90 min
at 37°C. This step was followed by washing and the addi-
tion of a secondary goat anti-mouse Fab-specific HRP con-
jugate (Sigma) diluted 1:5,000 in blocking buffer, with a
further incubation for 1.5 h at 37°C. Detection was per-
formed as above, and the percentage of specific inhibition
was calculated relative to buffer controls and by taking the
optical density of the well containing no competitor as
100%.
Mouse immune sera, mouse monoclonal antibodies and purified 
chicken polyclonal antibodies
As described above, ELISA plates were coated overnight at
4°C with 0.5 μg/ml or 0.25 μg/ml P1 for testing immune
sera and purified antibodies, respectively. The next morn-
ing, the plates were washed and blocked with blocking
buffer. V5B2 conjugated to HRP (V5B2-HRP), diluted
1:1,500, was separately mixed with different dilutions of
mice immune sera, Ab2 monoclonal antibodies, purified
chicken polyclonal antibodies (subsequently called Ch5)
or an isotype control antibody, and incubated for 1 h at
37°C prior to application to the blocked ELISA plate and
incubation for another 1 h at 37°C. After washing, the
detection step was carried out as described above, and
again, the percentage of specific inhibition was calculated
relative to buffer controls and by taking the optical density
of the well containing no competitor as 100%.
Immunohistochemistry
Tissue samples
Adjacent sections of paraformaldehyde-fixed, paraffin-
embedded human cerebellar tissue samples from a
patient with confirmed sporadic CJD (sCJD) with synaptic
prion deposition and primitive plaques (Val/Val on
codon 129 of the prion protein gene) were used in the
study, which were obtained from the archive of the Insti-
tute of Pathology, Faculty of Medicine, University of
Ljubljana. The tissue samples were immersed in 96% for-
mic acid for 1 h after fixing in paraformaldehyde. The 5-
μm-thick sections were used immediately after deparaffi-
nation and the antigen retrieval procedure involving 30
min autoclaving at 121°C in distilled water and then a 5-Page 11 of 14
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recommended pretreatment for optimal PrPSc immunode-
tection in tissue sections [52].
Competitive immunohistochemistry
Direct immunohistochemical detection of prion deposits
was performed with V5B2-HRP and using 3,3-diami-
nobenzidine as chromogen (Sigma). V5B2-HRP was
diluted 1:100 in a vehicle solution containing 1% BSA
(Sigma) and 0.04% Triton X-100 (Sigma) in phosphate
buffer, pH 7.2. Competitors at stated concentrations were
preincubated with V5B2-HRP in the same solution for 12
h at 4°C before applying the solution onto tissue sections,
which were then incubated overnight in a moist chamber
at room temperature. The sections were then rinsed thor-
oughly (10 × 10 min) and developed in chromogen for 5
min. Simultaneously processed sections incubated only in
vehicle buffer solution and developed in chromogen
served as a negative control.
Image collection and analysis
Photomicrographs were taken using 20 × objective on a
Nikon Eclipse E600 microscope equipped with a Nikon
DXM 1200 digital camera, and connected to a personal
computer station running NIS-D software. Every section
was photographed at 5 locations, chosen to always reveal
cerebellar cortical layers in balanced proportions.
Images of the brown immunoreactive product were
smoothed with Gaussian kernel (1 pixel radius), inverted
and colour-hue adjusted (the hue was rotated by 272°) to
transform the brown immunoreactive product on a white
background to a green signal on a black background. All
of the image pre-processing was accomplished in Adobe
Photoshop CS3 (Adobe, San Jose, CA, USA) using an
automated action. All further analysis was conducted on
the green signal intensity only. To establish a baseline
from which signal was estimated, a threshold was chosen
at which only 0.1% of the negative control image surface
remained above threshold. All images were then thresh-
olded (all pixels with intensity below the threshold were
set to 0) and the mean signal value for each image was
computed. To remove the effects of the remaining noise,
the mean signal value of negative control images (n = 5)
was subtracted from each image value. Finally, to express
the signal intensities as percentages of the positive control
intensity, the mean intensity values were divided by the
mean positive control intensity (uncompeted immuno-
histochemistry with V5B2-HRP) and multiplied by 100.
All of the image intensity analysis was carried out using
Matlab (Mathworks, Natick, MA, USA).
Statistical analysis of immunohistochemical data
The differences in effects of different competitor mole-
cules were estimated using one-way ANOVA. To test for
significant differences in intensities between test samples
and the positive control, a one-tailed t-test for independ-
ent samples with unequal variances was used. Based on
the number of tests, a Bonferroni corrected p value of
0.004 was chosen as the threshold for statistical signifi-
cance.
Polymerase chain reaction amplification and sequence 
analysis of heavy and light chains
Amplification and sequencing of monoclonal Ab2 anti-
body heavy and light chains were performed as described
by Koren et al. [53]. All of the nucleotide sequence analy-
ses and translations were carried out using the BioEdit
programme [54] or the ExPASy proteomics server [55]. All
of the immunoglobulin gene analyses were performed
using IMGT, the international ImMunoGeneTics informa-
tion system [56].
Antibody modeling and molecular docking
The variable regions of V5B2 and 5D12 were modeled fol-
lowing the procedure described by Morea et al. [57]. For
V5B2, relevant chains from Protein Data Bank (PDB)
structures 1KB5 and 1NBV were used as the light and
heavy chain variable regions (VL and VH) templates, show-
ing 94.5% and 92.7% similarity to the corresponding
V5B2 sequences, respectively. The H3 hypervariable loop
was modeled separately, using H3 loop from the PDB
structure 1VFA as the closest match of the same length and
torso conformation, with 53.8% similarity. For 5D12,
PDB structures 2PCP, 1FSK and 1DBA were used as the
templates for VL, VH and H3 loop, with the similarities to
the corresponding 5D12 sequences being 97.5%, 85.9%
and 73.3%, respectively. All similarities were calculated
using the BLOSUM62 matrix All structure manipulations
were carried out in Swiss-PdbViewer [58] and UCSF Chi-
mera [59].
The 5D12 and V5B2 variable region models were docked
using Patchdock molecular docking algorithm based on
shape complementarity principles [60], with the anti-
body-antigen complex type option enabled. The 5D12
model was specified as the antibody and the V5B2 model
as the antigen. One hundred best ranking solutions were
further refined and scored according to a binding energy
function using the Firedock algorithm [61].
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monoclonal antibody V5B2; vCJD: variant Creutzfeldt-
Jakob disease.
Authors' contributions
ACV carried out the murine immunizations, antibody
selection and characterization, participated in the design
of the study and drafted the manuscript. MB participated
in the design of competitive immunohistochemical stud-
ies and carried out the image collection, analysis and sta-
tistical analysis of immunohistochemical data. TV carried
out the immunohistochemical study and participated in
the design of the study. SK carried out the antibody mod-
elling and molecular docking. MN carried out the chicken
immunizations and cell fusion experiment. MP partici-
pated in evaluation of immunohistochemical results. VCS
conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank to Dr. Grega Repovš for expert advice and assist-
ance with image analysis, Dr. Mascia Ghielmetti for critical comments and 
ideas, and for carefully reading the manuscript, Miha Kosmaè for valuable 
input, Prof. Dr. Marko Dolinar for experimental advice and scientific discus-
sions, and members of our laboratory for their help and encouragement. 
The work was funded by Slovenian Research Agency grants L3-3435, L6-
6006 and L3-0206, and PhD grants for A.C.V. and S.K.
References
1. Jerne NK: Towards a network theory of the immune system.
Ann Immunol (Paris) 1974, 125C:373-89.
2. Nisonoff A: Idiotypes: concepts and applications.  J Immunol
1991, 147:2429-38.
3. Pan Y, Yuhasz SC, Amzel LM: Anti-idiotypic antibodies: biologi-
cal function and structural studies.  Faseb J 1995, 9:43-9.
4. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D: Monoclonal
anti-idiotypic antibodies as functional internal images of
enzyme active sites: production of a catalytic antibody with
a cholinesterase activity.  Proc Natl Acad Sci USA 1993, 90:8876-80.
5. Kolesnikov AV, Kozyr AV, Alexandrova ES, Koralewski F, Demin AV,
Titov MI, Avalle B, Tramontano A, Paul S, Thomas D, Gabibov AG,
Friboulet A: Enzyme mimicry by the antiidiotypic antibody
approach.  Proc Natl Acad Sci USA 2000, 97:13526-31.
6. Poljak RJ: An idiotope – anti-idiotope complex and the struc-
tural basis of molecular mimicking.  Proc Natl Acad Sci USA 1994,
91:1599-600.
7. Vani J, Nayak R, Shaila MS: Maintenance of antigen-specific
immunological memory through variable regions of heavy
and light chains of anti-idiotypic antibody.  Immunology 2007,
120:486-96.
8. Ponomarenko NA, Pillet D, Paon M, Vorobiev II, Smirnov IV, Adenier
H, Avalle B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Fri-
boulet A: Anti-idiotypic antibody mimics proteolytic function
of parent antigen.  Biochemistry 2007, 46:14598-609.
9. Collinge J: Prion diseases of humans and animals: their causes
and molecular basis.  Annu Rev Neurosci 2001, 24:519-50.
10. Prusiner SB: Prions.  Proc Natl Acad Sci USA 1998, 95:13363-83.
11. Prusiner SB: Novel proteinaceous infectious particles cause
scrapie.  Science 1982, 216:136-44.
12. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey
LJ, Lantos P: The same prion strain causes vCJD and BSE.
Nature 1997, 389:448-50.
13. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alpero-
vitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant
of Creutzfeldt-Jakob disease in the UK.  Lancet 1996, 347:921-5.
14. Aucouturier P, Carp RI, Carnaud C, Wisniewski T: Prion diseases
and the immune system.  Clin Immunol 2000, 96:79-85.
15. Porter DD, Porter HG, Cox NA: Failure to demonstrate a
humoral immune response to scrapie infection in mice.  J
Immunol 1973, 111:1407-10.
16. Magri G, Clerici M, Dall'Ara P, Biasin M, Caramelli M, Casalone C,
Giannino ML, Longhi R, Piacentini L, Della Bella S, Gazzuola P, Martino
PA, Della Bella S, Pollera C, Puricelli M, Servida F, Crescio I, Boasso
A, Ponti W, Poli G: Decrease in pathology and progression of
scrapie after immunisation with synthetic prion protein pep-
tides in hamsters.  Vaccine 2005, 23:2862-8.
17. Souan L, Tal Y, Felling Y, Cohen IR, Taraboulos A, Mor F: Modula-
tion of proteinase-K resistant prion protein by prion peptide
immunization.  Eur J Immunol 2001, 31:2338-46.
18. Schwarz A, Kratke O, Burwinkel M, Riemer C, Schultz J, Henklein P,
Bamme T, Baier M: Immunisation with a synthetic prion pro-
tein-derived peptide prolongs survival times of mice orally
exposed to the scrapie agent.  Neurosci Lett 2003, 350:187-9.
19. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R,
Meeker HC, Frangione B, Wisniewski T: Immunization delays the
onset of prion disease in mice.  Am J Pathol 2002, 161:13-7.
20. Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N,
Wopfner F, Schatzl HM, Becher B, Aguzzi A: Humoral immune
response to native eukaryotic prion protein correlates with
anti-prion protection.  Proc Natl Acad Sci USA 2004, 101(Suppl
2):14670-6.
21. Heppner FL, Aguzzi A: Recent developments in prion immuno-
therapy.  Curr Opin Immunol 2004, 16:594-8.
22. Gregoire S, Bergot AS, Feraudet C, Carnaud C, Aucouturier P, Ros-
set MB: The murine B cell repertoire is severely selected
against endogenous cellular prion protein.  J Immunol 2005,
175:6443-9.
23. Vranac T, Hartman KP, Popovic M, Venturini A, Zerovnik E, Curin
Serbec V: A single prion protein peptide can elicit a panel of
isoform specific monoclonal antibodies.  Peptides 2006,
27:2695-705.
24. Жurin Šerbec V, Bresjanac M, Popović M, Pretnar Hartman K, Galvani
V, Rupreht R, Жernilec M, Vranac T, Hafner I, Jerala R: Monoclonal
antibody against a peptide of human prion protein discrimi-
nates between Creutzfeldt-Jacob's disease-affected and nor-
mal brain tissue.  J Biol Chem 2004, 279:3694-8.
25. Poklar Ulrih N, Skrt M, Veranic P, Galvani V, Vranac T, Curin Serbec
V: Oligomeric forms of peptide fragment PrP(214–226) in
solution are preferentially recognized by PrP(Sc)-specific
antibody.  Biochem Biophys Res Commun 2006, 344:1320-6.
26. Жernilec M, Vranac T, Hafner-Bratkovic I, Koren S, Colja Venturini
A, Popović M, Juntes P, Жurin Šerbec V: Identification of an
epitope on the recombinant bovine PrP that is able to elicit
a prominent immune response in wild-type mice.  Immunol Lett
2007, 113:29-39.
27. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA: Anti-idiotype
vaccine against cancer.  Immunol Lett 2000, 74:51-8.
28. Magliani W, Polonelli L, Conti S, Salati A, Rocca PF, Cusumano V,
Mancuso G, Teti G: Neonatal mouse immunity against group B
streptococcal infection by maternal vaccination with recom-
binant anti-idiotypes.  Nat Med 1998, 4:705-9.
29. Pride MW, Shi H, Anchin JM, Linthicum DS, LoVerde PT, Thakur A,
Thanavala Y: Molecular mimicry of hepatitis B surface antigen
by an anti-idiotype-derived synthetic peptide.  Proc Natl Acad
Sci USA 1992, 89:11900-4.Page 13 of 14
(page number not for citation purposes)
BMC Immunology 2009, 10:16 http://www.biomedcentral.com/1471-2172/10/16Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
30. Lesinski GB, Westerink MA: Novel vaccine strategies to T-inde-
pendent antigens.  J Microbiol Methods 2001, 47:135-49.
31. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattach-
arya-Chatterjee M: Immune response to the carcinoembryonic
antigen in patients treated with an anti-idiotype antibody
vaccine.  J Clin Invest 1995, 96:334-42.
32. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S,
Anstee D, Collinge J, Hawke S: Monoclonal antibodies inhibit
prion replication and delay the development of prion dis-
ease.  Nature 2003, 422:80-3.
33. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-
Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek
RA, Burton DR, Prusiner SB: Antibodies inhibit prion propaga-
tion and clear cell cultures of prion infectivity.  Nature 2001,
412:739-43.
34. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zink-
ernagel RM, Kalinke U, Aguzzi A: Prevention of scrapie patho-
genesis by transgenic expression of anti-prion protein
antibodies.  Science 2001, 294:178-82.
35. Enari M, Flechsig E, Weissmann C: Scrapie prion protein accumu-
lation by scrapie-infected neuroblastoma cells abrogated by
exposure to a prion protein antibody.  Proc Natl Acad Sci USA
2001, 98:9295-9.
36. Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, Tayebi M,
Jackson GS, Clarke AR, Laude H, Collinge J, Hawke S: PrPSc binding
antibodies are potent inhibitors of prion replication in cell
lines.  J Biol Chem 2004, 279:39671-6.
37. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M,
Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E,
Gilden D, Oldstone MB, Conti B, Williamson RA: Cross-linking cel-
lular prion protein triggers neuronal apoptosis in vivo.  Science
2004, 303:1514-6.
38. Korth C, Stierli B, Streit P, Moser M, Schaller O, Fischer R, Schulz-
Schaeffer W, Kretzschmar H, Raeber A, Braun U, Ehrensperger F,
Hornemann S, Glockshuber R, Riek R, Billeter M, Wuthrich K, Oesch
B: Prion (PrPSc)-specific epitope defined by a monoclonal
antibody.  Nature 1997, 390:74-7.
39. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou
WQ, Estey LA, Lamontagne J, Lehto MT, Kondejewski LH, Francoeur
GP, Papadopoulos M, Haghighat A, Spatz SJ, Head M, Will R, Ironside
J, O'Rourke K, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR:
A prion protein epitope selective for the pathologically mis-
folded conformation.  Nat Med 2003, 9:893-9.
40. Moroncini G, Kanu N, Solforosi L, Abalos G, Telling GC, Head M,
Ironside J, Brockes JP, Burton DR, Williamson RA: Motif-grafted
antibodies containing the replicative interface of cellular PrP
are specific for PrPSc.  Proc Natl Acad Sci USA 2004, 101:10404-9.
41. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J: Heterogeneity
of monoclonal antibodies.  J Pharm Sci 2008, 97:2426-47.
42. Polonelli L, Seguy N, Conti S, Gerloni M, Bertolotti D, Cantelli C,
Magliani W, Cailliez JC: Monoclonal yeast killer toxin-like candi-
dacidal anti-idiotypic antibodies.  Clin Diagn Lab Immunol 1997,
4:142-6.
43. Depraetere H, Depla E, Haelewyn J, De Ley M: An anti-idiotypic
antibody with an internal image of human interferon-
gamma and human interferon-gamma-like antiviral activity.
Eur J Biochem 2000, 267:2260-7.
44. Ban N, Escobar C, Garcia R, Hasel K, Day J, Greenwood A, McPher-
son A: Crystal structure of an idiotype-anti-idiotype Fab com-
plex.  Proc Natl Acad Sci USA 1994, 91:1604-8.
45. Bruck C, Co MS, Slaoui M, Gaulton GN, Smith T, Fields BN, Mullins
JI, Greene MI: Nucleic acid sequence of an internal image-
bearing monoclonal anti-idiotype and its comparison to the
sequence of the external antigen.  Proc Natl Acad Sci USA 1986,
83:6578-82.
46. Garcia KC, Desiderio SV, Ronco PM, Verroust PJ, Amzel LM: Recog-
nition of angiotensin II: antibodies at different levels of an idi-
otypic network are superimposable.  Science 1992, 257:528-31.
47. Terčič D, Holcman A, Dorrer D, Kovač M: Reproduction charac-
teristics of cocks after 15 and 16 generations of the two way
selection on the chickens body weight.  Zootehnika, Agricultural
issue, Zootechnica 1994, 64:89-97.
48. Yoshitake S, Imagawa M, Ishikawa E, Niitsu Y, Urushizaki I, Nishiura
M, Kanazawa R, Kurosaki H, Tachibana S, Nakazawa N, Ogawa H:
Mild and efficient conjugation of rabbit Fab' and horseradish
peroxidase using a maleimide compound and its use for
enzyme immunoassay.  J Biochem 1982, 92(5):1413-1424.
49. Matsuda H, Mitsuda H, Nakamura N, Furusawa S, Mohri S, Kitamoto
T: A chicken monoclonal antibody with specificity for the N-
terminal of human prion protein.  FEMS Immunol Med Microbiol
1999, 23:189-94.
50. Matsushita K, Horiuchi H, Furusawa S, Horiuchi M, Shinagawa M, Mat-
suda H: Chicken monoclonal antibodies against synthetic
bovine prion protein peptide.  J Vet Med Sci 1998, 60:777-9.
51. Beatty JD, Beatty BG, Vlahos WG: Measurement of monoclonal
antibody affinity by non-competitive enzyme immunoassay.
J Immunol Methods 1987, 100:173-9.
52. Hegyi I, Hainfellner JA, Flicker H, Ironside JW, Hauw JJ, Tateishi J,
Haltia M, Bugiani O, Aguzzi A, Budka H: Prion protein immunocy-
tochemistry: reliable staining protocol, immunomorphol-
ogy, and diagnostic pitfalls.  Clin Neuropathol 1997, 16:262-263.
53. Koren S, Kosmac M, Colja Venturini A, Montanic S, Curin Serbec V:
Antibody variable-region sequencing as a method for hybri-
doma cell-line authentication.  Appl Microbiol Biotechnol 2008,
78:1071-8.
54. Hall TA: BioEdit: a user-friendly biological sequence align-
ment editor and analysis program for Windows 95/98/NT.
Nucleic Acids Symposium Series 1999, 41:95-98.
55. ExPASy proteomics server   [http://www.expasy.org]
56. International ImMunoGeneTics information system   [http://
imgt.cines.fr/]
57. Morea V, Lesk AM, Tramontano A: Antibody modeling: implica-
tions for engineering and design.  Methods 2000, 20:267-79.
58. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-Pdb-
Viewer: an environment for comparative protein modeling.
Electrophoresis 1997, 18:2714-23.
59. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM,
Meng EC, Ferrin TE: UCSF Chimera – a visualization system for
exploratory research and analysis.  J Comput Chem 2004,
25:1605-12.
60. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ: Patch-
Dock and SymmDock: servers for rigid and symmetric dock-
ing.  Nucleic Acids Res 2005, 33:W363-7.
61. Mashiach E, Schneidman-Duhovny D, Andrusier N, Nussinov R, Wolf-
son HJ: FireDock: a web server for fast interaction refinement
in molecular docking.  Nucleic Acids Res 2008, 36:W229-32.Page 14 of 14
(page number not for citation purposes)
